CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company
Replimune Group, Inc.
Sign in to watch- Ticker
- REPL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822082553
- Phone
- (781) 222-9600
- Business address
- 500 UNICORN PARK, WOBURN, MA, 01801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $654,036
- in 3 filings
Net −$654,036. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-09 | SLATTERY JOSEPH P Director | Sale | −5,200 | $21.80 | $113K | 1,467 |
| 2026-11-02 | Dhingra Kapil Director | Option exercise | +43,169 | $1.75 | $76K | 43,169 |
| 2026-11-02 | Dhingra Kapil Director | Sale | −21,500 | $19.00 | $409K | 21,669 |
| 2026-11-02 | Dhingra Kapil Director | Option exercise · Stock Option (right to buy) | −43,169 | 0 | ||
| 2026-08-20 | Astley-Sparke Philip Director | Gift | −50,000 | 1,362,414 | ||
| 2026-08-17 | Hill Emily Luisa Chief Financial Officer | Sale | −9,256 | $14.28 | $132K | 215,852 |
| 2026-08-11 | BAKER BROS. ADVISORS LP Director | Purchase · 2026 $0.0001 Prefunded Warrants | +126,394 | $12.06 | $1.5M | 126,394 |
| 2026-08-11 | BAKER BROS. ADVISORS LP Director | Purchase · 2026 $0.0001 Prefunded Warrants | +2,609,946 | $12.06 | $31.5M | 2,609,946 |
| 2026-08-10 | Patel Sushil Chief Executive Officer | Sale | −39,341 | $12.97 | $510K | 708,151 |
| 2026-08-10 | Hill Emily Luisa Chief Financial Officer | Sale | −11,448 | $12.97 | $148K | 225,108 |
| 2026-08-10 | Xynos Konstantinos Chief Medical Officer | Sale | −11,447 | $12.97 | $148K | 224,215 |
| 2026-08-10 | Schwendenman Andrew Chief Accounting Officer | Sale | −7,632 | $12.97 | $99K | 99,425 |
| 2026-06-01 | Sarchi Christopher Chief Commercial Officer | Sale 10b5-1 | −12,000 | $9.24 | $111K | 180,962 |
| 2026-05-18 | Xynos Konstantinos Chief Medical Officer | Sale | −14,023 | $5.08 | $71K | 235,662 |
| 2026-05-18 | Schwendenman Andrew Chief Accounting Officer | Sale | −7,894 | $5.08 | $40K | 107,057 |
| 2026-05-18 | Sarchi Christopher Chief Commercial Officer | Sale | −8,626 | $5.08 | $44K | 192,962 |
| 2026-05-18 | Astley-Sparke Philip Director | Sale | −17,657 | $5.08 | $90K | 1,412,414 |
| 2026-05-18 | Patel Sushil Chief Executive Officer | Sale | −37,324 | $5.08 | $190K | 747,492 |
| 2026-05-18 | Hill Emily Luisa Chief Financial Officer | Sale | −7,812 | $5.08 | $40K | 236,556 |
| 2026-04-02 | Sarchi Christopher Chief Commercial Officer | Sale 10b5-1 | −6,500 | $8.01 | $52K | 151,588 |
Page 1 of 8 · 143 trades